Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC
Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Nov 10, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to study the role of certain immune cells, called senescent T lymphocytes, in young women with triple-negative breast cancer (TNBC) who are receiving chemotherapy. The researchers want to understand how these cells change during treatment and how they might affect the success of chemotherapy, as well as any side effects that may occur. Participants in the trial will undergo six cycles of chemotherapy followed by surgery to remove the tumor, and their blood will be collected at different points during this process to monitor changes in their immune cells.
To qualify for the study, participants must be female and 40 years old or younger, with a confirmed diagnosis of invasive TNBC. They should have a tumor larger than 2 cm or have cancer that has spread to nearby lymph nodes. Women who have other serious health conditions, such as infections or previous cancers, or who have had surgery recently, won't be eligible. This study is not yet recruiting participants, but once it starts, those involved can expect regular check-ups during their treatment to help track their health and the effects of chemotherapy.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Female, age≤40 years old,
- • 2. Invasive breast cancer confirmed by pathology, immunohistochemistry showed TNBC (ER-, PR-, HER2-),
- • 3. Indications for neoadjuvant chemotherapy according to guidelines: tumor diameter \> 2cm or with axillary lymph node metastasis or desiring breast-conserving surgery but should obtain negative surgical margins through neoadjuvant chemotherapy.
- Exclusion Criteria:
- • 1. Stage IV patients or a history of other malignancies,
- • 2. Having microbial infection or autoimmune disease have not been cured or having HBV, HIV infection,
- • 3. Having surgery 3 months before enrollment,
- • 4. Patients with insufficient clinicopathological data,
- • 5. Does not meet the indications for neoadjuvant chemotherapy or is unwilling to cooperate.
About The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is a leading academic medical institution in China, renowned for its commitment to advanced healthcare, research, and medical education. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to facilitate innovative medical research aimed at improving patient outcomes. With a focus on translational medicine, the institution fosters collaborations between clinicians and researchers to accelerate the development of novel therapies and enhance the understanding of complex diseases. Through its rigorous adherence to ethical standards and regulatory compliance, the hospital is dedicated to advancing medical knowledge and contributing to the global scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported